FDA's 510(k) Action Plan Draws Praise, Criticism from Proteomics Diagnostics Community

The plan, which the agency made public on Jan. 19, detailed a number of draft guidances FDA intends to put out this year; but it's the items that it declined to address, like the development of a new Class IIb device category, that could be the most significant.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.